Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Markets Businessinsider

Published November 13, 2026 · Updated November 14, 2026

GH Research Reports Third Quarter 2026 Financial Results and Provides Business Update

Read the full story at Markets Businessinsider

Such forward-looking statements contained in this press release speak only as of the date hereof. ... Psychedelic : Compass Pathways beats Q3 loss.

Surfaced by this Google Alert

  • Psychedelic press release